Part 3 – Case Discussion & Wrap-up

Erin Schenk, MD, PhD, and D. Ross Camidge, MD, PhD, medical oncologists at the University of Colorado Cancer Center, continue to discuss treatment options for a 53-year-old woman with advanced stage IIIC NSCLC. Drs Schenk and Camidge discuss treatment goals for this patient and the use of immunotherapy. Hypothetical treatment scenarios are also discussed.

Visit this link to continue to Part 3 – Case Discussion & Wrap-up.

Disclosures:

Erin Schenk, MD, PhD
Consulting Fees: Guidepoint, Physicians’ Education Resource

D. Ross Camidge, MD, PhD
Consulting Fees: Amgen, Anchiarno, Apollomics, AstraZeneca, Bio-Thera, BMS, Daiichi-Sankyo, Eisai, Elevation, Eli Lilly, EMD Serono, GSK, Helssin, Janssen, Nuvalent, Onkure, Mersana, Pfizer, Qilu, Roche, Sanofi, Seattle Genetics, Takeda
Contracted Research: AbbVie, AstraZeneca, BMS, GSK, Hansoh, Inhibrx, Inivata, Karyopharm, Lycera, Medimmune, Merck, Pfizer, Phosplatin, Psioxus, Rain, Roche/Genentech, Seattle Genetics, Symphogen, Takeda, Tolero